

Company Overview

CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing.

Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.

Our mission at CollPlant is to deliver ground-breaking products for regenerative medicine that offer the optimal treatment options to patients.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES \$2.0 MILLION REGISTERED DIRECT OFFERING

Feb 5 2026, 8:00 AM EST

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Nov 26 2025, 7:30 AM EST

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS

Nov 18 2025, 7:00 AM EST

Stock Overview

| | |
|---------------|-----------------|
| Symbol | CLGN |
| Exchange | Nasdaq |
| Market Cap | 9.58m |
| Last Price | \$0.75 |
| 52-Week Range | \$0.65 - \$4.98 |

02/05/2026 09:00 PM EST

Investor Relations

| |
|--|
| Eran Rotem |
| Deputy CEO & CFO |
| T: +972 (73) 2325612 |
| F: +972 (73) 2325602 |
| eran@collplant.com |

Management Team

Yehiel Tal

Chief Executive Officer, Interim Chairman

Prof. Oded Shoseyov

Founder, Chief Scientist

Eran Rotem, CPA

Deputy CEO and Chief Financial Officer

Dr. Philippe Bensimon

Vice President, Regulatory Affairs and Quality Assurance

Hadas Dreier Horowitz

Vice President of Human Resources

Oren Fahimipoor

Vice President of Operations

Bowman Bagley

Vice President Commercial, North America

CollPlant Biotechnologies Ltd.

4 Oppenheimer St.,
P.O.B 4132
Rehovot 7670104,
Israel

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.